Last reviewed · How we verify
NCT03704324: PREDICt
Incidence and Risk Factors of PostopeRativE Delirium in ICU in China
trial in Postoperative Delirium in 1,000 participants. Status unknown.
1 December 2022
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 November 2018 |
| Primary completion | 1 December 2022 |
| Estimated completion | 1 January 2023 |
| Sites | 1 location across China |
Conditions studied
- Postoperative Delirium — all drugs for Postoperative Delirium →
- Intensive Care Psychiatric Disorder — all drugs for Intensive Care Psychiatric Disorder →
Sponsor
Shanghai Zhongshan Hospital
Who can join
18 and older, any sex, with Postoperative Delirium or Intensive Care Psychiatric Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Postoperative delirium (POD) is a common postoperative complication that can occur in patients of any age. POD brings great burden to patients and their families, as the following cognitive decline may persist for months to years to impede patients returning to previous life quality and employment. The PREDICt study aims to characterize the incidence and profiles of POD in ICU, and to find out risk factors, especially any are modifiable, and any have value for developing prediction model. Our final aim is to comprehensively and deeply explore the etiology of POD to guide prevention of delirium among postoperative patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Early prediction of noninvasive ventilation failure after extubation: development and validation of a machine-learning model.
Wang H, Zhao QY, Luo JC, Liu K, et al · · 2022 · cited 16× · PMID 35941641 · DOI 10.1186/s12890-022-02096-7 -
Two-stage prediction model for postoperative delirium in patients in the intensive care unit after cardiac surgery.
Cai S, Cui H, Pan W, Li J, et al · · 2022 · cited 6× · PMID 36579859 · DOI 10.1093/ejcts/ezac573
Verify or expand the search:
- PubMed search for NCT03704324
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Postoperative Delirium
Currently open trials in the same condition.
- NCT07323485 — Inflammatory Biomarkers and Postoperative Delirium in Pediatric Circumcision · recruiting
- NCT07411794 — Dexmedetomidine vs Midazolam in Coronary Artery By-pass Surgery · NA · recruiting
- NCT07239648 — Postoperative Delirium in Patients Undergoing Cardiac Surgery · recruiting
- NCT07217912 — Daridorexant to Prevent Post-cardiotomy Delirium · Phase 2 · recruiting
- NCT07108764 — Intraoperative Infusion of Either Lidocaine or Dexmedetomidine on Regional Cerebral Oxygen Saturation and Postoperative · NA · recruiting
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03704324 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 3 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03704324.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing